NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
By Ann Grey
Dr. William Pao
Roche Names Industry Veteran to Lead Oncology Research
Roche has named William Pao, M.D., Ph.D., professor of medicine and head of the hematology-oncology division at Vanderbilt University Medical Center, to Roche Pharma Research and Early Development (pRED) as global head of the oncology disease and translational area (DTA). He is responsible for leading Roche’s discovery, translational medicine, and early development of innovative oncology medicines. In this capacity he contributes to maintaining Roche’s leadership in oncology.
Dr. Jeff Hrkach
Bind Therapeutics Promotes Key Executives
Bind Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team.
Andrew Hirsch has been appointed chief operating officer with expanded responsibilities, including program and alliance management and oversight of Bind’s Russian operations. He continues to serve as chief financial officer of the company.
Jeff Hrkach, Ph.D., formerly senior VP, technology research and development, has been promoted to chief technology officer with responsibility for the research, development, and manufacturing of Bind’s Accurin pipeline and research and technology development related to its medicinal nanoengineering platform.
Apricus Biosciences Expands Senior Management Team
Apricus Biosciences, a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men’s and women’s health, has appointed Neil Morton as VP of business development.
Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the executive director of business development at Auxilium Pharmaceuticals, where he successfully led the company’s efforts to build a pipeline of men’s health products.
Drug Discovery Pool
Dr. Carole Sable
Scynexis Appoints Chief Medical Officer
Drug discovery company Scynexis has appointed infectious disease expert Carole Sable, M.D., as chief medical officer.
Dr. Sable was most recently a VP at Merck & Co., as VP, project leadership and management in neurosciences and ophthalmology.
Dr. R. Weslie Tyson
CombiMatrix Hires Chief Medical Officer
CombiMatrix Corp., a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, has hired veteran pediatric pathologist R. Weslie Tyson, M.D., as chief medical officer.
Dr. Tyson has been a practicing pediatric and perinatal pathologist for 24 years. He comes to CombiMatrix from UniPath, a multispecialty pathology group.
PPD Enhances Management Team
PPD has appointed Patrick Bennett as executive director of laboratory operations for a new biomarker services division of its bioanalytical laboratory. Mr. Bennett is charged with leading and driving strategy for comprehensive biomarker development and testing from discovery through approval of predictive medicine biomarkers for both large and small molecule therapeutics. Most recently, Mr. Bennett was global strategic marketing director for pharma/biopharma life-sciences mass spectrometry at Thermo Fisher Scientific.
PPD also has appointed Michael Pollock VP of real world outcomes. Mr. Pollock is responsible for directing and enhancing PPD’s capabilities in health outcomes and evidence-based medicine to help biopharmaceutical clients optimize market and patient access to novel therapies. Most recently, Mr. Pollock was president of Reynolds Pollock & Associates, a health outcomes research and market access strategy consulting company.
AbelsonTaylor Hires Digital Pro
AbelsonTaylor, an independent advertising agency, has hired digital pro Emily Tower as VP of digital strategy and analytics.
She comes to AbelsonTaylor from Meredith Xcelerated Marketing, a consumer and healthcare digital marketing agency in New York, where she was senior director of client solutions, developing the launch and sales strategies for emerging biologics, novel rare disease treatments, and cardiovascular interventions.
HealthComGroup Announces New Executive VP
The HealthComGroup has hired William Mulderry as executive VP. HealthComGroup is a communications company focused on serving the health and wellness industry. Mr. Mulderry was most recently at Bulletin Healthcare, a digital news brief provider, where he successfully leveraged key pharmaceutical and association partnerships to expand the company’s business.
Exco InTouch Names VP of Operations
Exco InTouch, a provider of patient engagement and data capture solutions for clinical research and healthcare providers, has appointed Laurence Burke as VP of operations. Chief among his responsibilities is ensuring that processes are as streamlined and efficient as possible for customers, while ensuring full continuity of robust delivery programs. Mr. Burke is responsible for operations in servicing customers in the clinical, late phase, and mHealth fields.
Dr. Kate Earle
Adult Learning Expert to Head TGaS Training and Development Team
Kate Earle, Ph.D., an expert in adult learning, has been named to lead the TGaS Advisors training and development team, a division of the benchmarking and advisory firm’s sales advisory practice.
Before joining TGaS, Dr. Earle was director of sales effectiveness for VWR International, a research laboratory products company, where she provided consulting services and implementation of a successful comprehensive approach for a new sales competency framework, process, and methodology.
Dr. Stella Karantzoulis
PRophase adds to neurology team
Stella Karantzoulis, Ph.D., has joined ProPhase as the scientific lead for neurocognition. Dr. Karantzoulis specializes in the neuropsychological evaluation of memory disorders, dementia, and other neurobehavioral syndromes.
Dr. Karantzoulis joins as the scientific lead for neurocognition to build on ProPhase’s recent commercial successes in partnering to deliver highly customized solutions that support clinical trials in over 60 countries, in all phases, across 18 primary indications. ProPhase is a specialty services organization focusing on applied measurement in CNS.
QPharma Appoints Director, DEA Compliance and Services
QPharma, a compliance and commercial solutions firm serving the life-sciences industry, has appointed Matt Crusan to the position of director, DEA compliance and services. A former diversion investigator with the Drug Enforcement Administration (DEA), Mr. Crusan brings his extensive knowledge of DEA regulatory policy to his role as head of QPharma’s newly established DEA compliance practice.
Alexza Pharmaceuticals Names Executive VP, Operations and Chief Operations Officer Robert Lippe joins Alexza Pharmaceuticals as executive VP, operations and chief operations officer. In this newly created position, Mr. Lippe has responsibility for the company’s global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of its product and technology portfolio.
Dr. Ada Braun
Biothera Names Chief Medical Officer Biothera has appointed Ada Braun, M.D., Ph.D., as chief medical officer responsible for the clinical and regulatory development of Imprime PGG, the company’s Phase III cancer immunotherapy drug.
Most recently, Dr. Braun was executive medical director, global development, hematology/oncology at Amgen.
Dr. Mike Royal
Sorrento Therapeutics Hires Senior VP of Clinical Development
Sorrento Therapeutics, a late-stage clinical oncology company developing new treatments for cancer and associated pain, has named anesthesiologist and pain specialist, Mike Royal, M.D., senior VP of clinical development. He was most recently chief of clinical affairs at AcelRx.
Hall & Partners Names Global CEO of Health Business Hall & Partners has named Abigail Stuart as global CEO of Hall & Partners’ health business. With almost 20 years of specialist healthcare research experience, Ms. Stuart has focused her career on helping pharmaceutical companies develop brand strategy and communications for new and existing brands. She joined Hall & Partners in 1999 to help set up the specialized healthcare division in the London office.
Dr. Robert Aplin
Harvard Bioscience Names VP, Global Operations and Quality
Harvard Bioscience, a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to VP global operations and quality, a newly created position.
Mr. Aplin has more than 25 years experience in operations and supply chain management. He comes to Harvard Bioscience from Corning Inc., where he served as operations/plant manager
Human Care Systems Adds to Executive Ranks
Matthew Jones joins Human Care Systems as executive VP, global head business development, sales and marketing.
Mr. Jones is a life-sciences business executive whose 17-year healthcare industry experience has spanned clinical research; finance; international business development; business optimization, strategy and expansion; sales and marketing; and staff recruitment, training and management.
Before joining HCS, he held positions as VP global head sales and business development at Lonza Biologics.
Human Care Systems designs, develops, and deploys patient support programs to modify behavior and drive higher rates of adherence, improved health outcomes, and increased patient and HCP satisfaction.